Regeneron Pharmaceuticals (MEX:REGN) Issuance of Debt : MXN0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Regeneron Pharmaceuticals Issuance of Debt?

Regeneron Pharmaceuticals's Issuance of Debt for the three months ended in Dec. 2024 was MXN0 Mil.

Regeneron Pharmaceuticals's Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 was MXN0 Mil.

Regeneron Pharmaceuticals Issuance of Debt Historical Data

The historical data trend for Regeneron Pharmaceuticals's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Issuance of Debt Chart

Regeneron Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Issuance of Debt

Get a 7-Day Free Trial

69,261.96

Regeneron Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Issuance of Debt	Get a 7-Day Free Trial															-	-	-	-	-

Regeneron Pharmaceuticals Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0 Mil.

Regeneron Pharmaceuticals Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Regeneron Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (MEX:REGN) » Definitions » Issuance of Debt

Comparable Companies

Traded in Other Exchanges

REGN:USA 0R2M:UK RGO:Germany REGN34:Brazil REGN:Austria

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).